Haris Ali, M.D.
Hematologist-Oncologist
4.9 (145 RATINGS)
Clinical Expertise
Hematology
Hematologic Malignancies
Hematopoietic Cell Transplantation
Myeloproliferative Neoplasms
Acute Leukemias
Hematopoietic Cell Transplantation
Research Area
Myelofibrosis
Polycythemia Vera
Essential Thrombocythemia
Chronic Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Novel Treatment For Myeloproliferative Neoplasms Including Targeted And Immunotherapies
Prevention And Treatment Of Graft Versus Host Disease
Appointments
Associate Professor, Division Of Leukemia, Department Of Hematology And Hematopoietic Cell Transplantation
Clinical Teams
Research Teams
Haris Ali, M.D., joined the Department of Hematology and Hematopoietic Cell Transplantation (HCT) as assistant professor following the completion of his HCT fellowship here at City of Hope. Dr. Ali received his medical doctorate from Rawalpindi Medical College in Rawalpindi, Pakistan.
He completed an internal medicine internship at the University of Maryland's Harbor Hospital Center in Baltimore, followed by an internal medicine residency at Loma Linda University Medical Center, where he eventually was named chief resident and then stayed on for the next four years as an Instructor, and then Assistant Professor of Medicine.
Dr. Ali then decided to continue his training, completing a medical oncology/hematology fellowship at the University of Texas Southwestern Medical Center in Dallas, TX, before coming to City of Hope. During his fellowship, Dr. Ali received the Recognition Award for First Place in American Society of Clinical Oncology In-Service in 2011 and 2012, and the Recognition Award for First Place in American Society of Hematology In-Service Exam also in 2011 and 2012.
Dr. Ali is Board certified in internal medicine, medical oncology and hematology, and is available to see our patients with hematologic malignancy and BMT.
2001, M.D., Rawalpindi Medical College, Rawalpindi, Pakistan
2009-2012, University of Texas Southwest (Hematology/Medical Oncology)
2012-2013, Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2004-2007, Loma Linda University Medical Center, Loma Linda, CA
2003-2004, Intern, Internal Medicine, Harbor Hospital Center, University of Maryland, Baltimore, MD
2020-present, Associate Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation (HCT), City of Hope, Duarte, CA
2013-2020, Assistant Clinical Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation (HCT), City of Hope, Duarte, CA
2013-present, Staff Physician, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation (HCT), City of Hope, Duarte, CA
2011 & 2012, Recognition Award for First Place in American Society of Clinical Oncology In-service Exam
2011 & 2012, Recognition Award For First Place in American Society of Hematology In-service Exam
2006, Best Poster, American College of Physicians, California Chapter poster competition
2003, Winner Doctor’s Dilemma, American College of Physicians, Maryland Chapter
2001, Highest ranking medical school graduate, class rank 3rd of 250
1999, Distinction in pathology
American Society of Blood and Marrow Transplantation
American Society of Clinical Oncology
American Society of Hematology
Associate of American College Physician
- K.S. Sandhu, S. Dadwal, D. Yang, M. Mei, J. Palmer, A. Salhotra, M.A. Malki, A. Aribi, H. Ali, S. Khaled, S.J. Forman, D. Snyder, R. Nakamura, A.S. Stein, G. Marcucci, I. Aldoss, V. Pullarkat, Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia, Biology of Blood and Marrow Transplantation. 26 (2020) e322–e327.
- I. Aldoss, J. Zhang, M. Mei, M.M.A. Malki, S. Arslan, D. Ngo, A. Aribi, H. Ali, K. Sandhu, A. Salhotra, P. Koller, S. Khaled, A. Artz, D. Snyder, R. Nakamura, S.J. Forman, A.S. Stein, G. Marcucci, V. Pullarkat, Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia, American Journal of Hematology. 95 (2020) 1193–1199.
- A. Salhotra, D. Yang, S. Mokhtari, M.M.A. Malki, H. Ali, K.S. Sandhu, A. Aribi, S. Khaled, M. Mei, E. Budde, D. Snyder, T. Cao, R. Spielberger, G. Marcucci, V. Pullarkat, S.J. Forman, R. Nakamura, A. Stein, I. Aldoss, Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia, Biology of Blood and Marrow Transplantation. 26 (2020) 1084–1090.
- K. Gowin, K. Ballen, K.W. Ahn, Z.H. Hu, H. Ali, M.O. Arcasoy, R. Devlin, M. Coakley, A.T. Gerds, M. Green, V. Gupta, G. Hobbs, T. Jain, M. Kandarpa, R. Komrokji, A.T. Kuykendall, K. Luber, L. Masarova, L.C. Michaelis, S. Patches, A.C. Pariser, R. Rampal, B. Stein, M. Talpaz, S. Verstovsek, M. Wadleigh, V. Agrawal, M. Aljurf, M.A. Diaz, B.R. Avalos, U. Bacher, A. Bashey, A.M. Beitinjaneh, J. Cerny, S. Chhabra, E. Copelan, C.S. Cutler, Z. DeFilipp, S.M. Gadalla, S. Ganguly, M.R. Grunwald, S.K. Hashmi, M.A. Kharfan-Dabaja, T. Kindwall-Keller, N. Krger, H.M. Lazarus, J.L. Liesveld, M.R. Litzow, D.I. Marks, S. Nathan, T. Nishihori, R.F. Olsson, A. Pawarode, J.M. Rowe, B.N. Savani, M.L. Savoie, S. Seo, M. Solh, R. Tamari, L.F. Verdonck, J.A. Yared, E. Alyea, U. Popat, R. Sobecks, B.L. Scott, R. Nakamura, R. Mesa, W. Saber, Survival following allogeneic transplant in patients with myelofibrosis, Blood Advances. 4 (2020) 1966–1973.
- M. Jagasia, M.A. Perales, M.A. Schroeder, H. Ali, N.N. Shah, Y.B. Chen, S. Fazal, F.W. Dawkins, M.C. Arbushites, C. Tian, L. Connelly-Smith, M.D. Howell, H.J. Khoury, Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1) : a multicenter, open-label phase 2 trial, Blood. 135 (2020) 1739–1749.
- H. Ali, A. Salhotra, B. Modi, R. Nakamura, Ruxolitinib for the treatment of graft-versus-host disease, Expert Review of Clinical Immunology. 16 (2020) 347–359.
- M.A. Schroeder, H.J. Khoury, M. Jagasia, H. Ali, G.J. Schiller, K. Staser, J. Choi, L. Gehrs, M.C. Arbushites, Y. Yan, P. Langmuir, N. Srinivas, M. Pratta, M.-A. Perales, Y.-B. Chen, G. Meyers, J.F. DiPersio, A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease, Blood Advances. 4 (2020) 1657–1669.
- A. Salhotra, S. Hui, D. Yang, S. Mokhtari, M. Mei, M.M.A. Malki, I. Aldoss, H. Ali, K.S. Sandhu, A. Aribi, S. Khaled, S. Dandapani, K. Peng, J.B. Teh, J. Murata-Collins, E. Budde, S. Dadwal, V. Pullarkat, D. Snyder, R. Spielberger, J. Wong, S. Armenian, G. Marcucci, S.J. Forman, R. Nakamura, A. Stein, Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen : 6-Year Follow-Up from a Single Center, Biology of Blood and Marrow Transplantation. 26 (2020) 292–299.
- M. Mei, N.-C. Tsai, S. Mokhtari, M.M.A. Malki, H. Ali, A. Salhotra, K. Sandhu, S. Khaled, E. Smith, D. Snyder, G. Marcucci, S.J. Forman, V. Pullarkat, A. Stein, I. Aldoss, R. Nakamura, Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia, Biology of Blood and Marrow Transplantation. (2020).
- I. Aldoss, S. Dadwal, J. Zhang, B. Tegtmeier, M. Mei, S. Arslan, M.M.A. Malki, A. Salhotra, H. Ali, A. Aribi, K. Sandhu, S. Khaled, D. Snyder, R. Nakamura, A.S. Stein, S.J. Forman, G. Marcucci, V. Pullarkat, Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents, Blood Advances. 3 (2019) 4043–4049.
- R. Gupta, F. Jamal, D. Yang, C. Chendri, I. Aldoss, M.A. Malki, M. Mei, A. Salhotra, S. Dobrin, M. Tran, K. Venkataraman, J. Palmer, A.S. Stein, K. Sandhu, S. Khaled, A. Aribi, G. Marcucci, S.J. Forman, D. Snyder, R. Nakamura, H. Ali, V. Pullarkat, Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis, Bone Marrow Transplantation. 55 (2019) 877–883.
- A. Salhotra, M. Afkhami, D. Yang, S. Mokhtari, M. Telatar, D. Gu, R.K. Pillai, D.D. Weisenburger, J. Mu
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
4.9
Show respect for what you say
4.9
Provider listen carefully to you
4.8
Know important info medical history
4.8
Spend enough time with you
4.8
Rate provider 0-10
4.8
Recommend this provider office
4.8
Provider explain in way you understand
Reviews
01/15/23
Everyone is very nice and they are very caring they are hands on at all time . - Verified patient
11/22/22
Dr. Ali and his team have kept me alive for over 4 years. I am very grateful for that. - Verified patient
11/19/22
I can't say enough about my doctor and his staff. Awesome staff. - Verified patient
09/06/22
The answer to the above questions are based on what was reported by the nurse who apparently left the room and consulted with Dr. Ali. It's somewhat difficult to complete this questionnaire as I did not actually see Dr. Ali during this visit. - Verified patient
06/28/22
Good - Verified patient